PMID- 23411799
OWN - NLM
STAT- MEDLINE
DCOM- 20130418
LR  - 20221109
IS  - 1474-1741 (Electronic)
IS  - 1474-1733 (Linking)
VI  - 13
IP  - 3
DP  - 2013 Mar
TI  - Intravenous immunoglobulin therapy: how does IgG modulate the immune system?
PG  - 176-89
LID - 10.1038/nri3401 [doi]
AB  - Intravenous immunoglobulin (IVIG) preparations comprise pooled IgG antibodies 
      from the serum of thousands of donors and were initially used as an IgG 
      replacement therapy in immunocompromised patients. Since the discovery, more than 
      30 years ago, that IVIG therapy can ameliorate immune thrombocytopenia, the use 
      of IVIG preparations has been extended to a wide range of autoimmune and 
      inflammatory diseases. Despite the broad efficacy of IVIG therapy, its modes of 
      action remain unclear. In this Review, we cover the recent insights into the 
      molecular and cellular pathways that are involved in IVIG-mediated 
      immunosuppression, with a particular focus on IVIG as a therapy for IgG-dependent 
      autoimmune diseases.
FAU - Schwab, Inessa
AU  - Schwab I
AD  - Institute of Genetics, Department of Biology, University of Erlangen-Nurnberg, 
      Erwin-Rommelstrasse 3, 91058 Erlangen, Germany.
FAU - Nimmerjahn, Falk
AU  - Nimmerjahn F
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20130215
PL  - England
TA  - Nat Rev Immunol
JT  - Nature reviews. Immunology
JID - 101124169
RN  - 0 (Autoantibodies)
RN  - 0 (Cell Adhesion Molecules)
RN  - 0 (DC-specific ICAM-3 grabbing nonintegrin)
RN  - 0 (Histocompatibility Antigens Class I)
RN  - 0 (Immunoglobulin Fc Fragments)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Immunoglobulin Variable Region)
RN  - 0 (Immunoglobulins, Intravenous)
RN  - 0 (Lectins, C-Type)
RN  - 0 (Receptors, Cell Surface)
RN  - 0 (Receptors, Fc)
RN  - 0 (Receptors, IgG)
RN  - GZP2782OP0 (N-Acetylneuraminic Acid)
RN  - TW3XAW0RCY (Fc receptor, neonatal)
SB  - IM
CIN - Nat Rev Immunol. 2014 May;14(5):349. PMID: 24762828
CIN - Nat Rev Immunol. 2014 May;14(5):349. PMID: 24762829
MH  - Animals
MH  - Autoantibodies/immunology
MH  - Autoimmune Diseases/immunology/therapy
MH  - Cell Adhesion Molecules/immunology
MH  - Clinical Trials as Topic
MH  - Disease Models, Animal
MH  - Glycosylation
MH  - Histocompatibility Antigens Class I/immunology
MH  - Humans
MH  - Immunocompromised Host
MH  - Immunoglobulin Fc Fragments/immunology
MH  - Immunoglobulin G/immunology/pharmacology/*therapeutic use
MH  - Immunoglobulin Variable Region/immunology
MH  - Immunoglobulins, Intravenous/pharmacology/*therapeutic use
MH  - Immunomodulation/*drug effects/immunology
MH  - *Immunosuppression Therapy
MH  - Inflammation/immunology/therapy
MH  - Lectins, C-Type/immunology
MH  - Lymphocyte Subsets/immunology
MH  - Mice
MH  - Models, Molecular
MH  - N-Acetylneuraminic Acid/immunology
MH  - Protein Conformation
MH  - Protein Processing, Post-Translational
MH  - Receptors, Cell Surface/immunology
MH  - Receptors, Fc/immunology
MH  - Receptors, IgG/chemistry/classification/immunology
EDAT- 2013/02/16 06:00
MHDA- 2013/04/20 06:00
CRDT- 2013/02/16 06:00
PHST- 2013/02/16 06:00 [entrez]
PHST- 2013/02/16 06:00 [pubmed]
PHST- 2013/04/20 06:00 [medline]
AID - nri3401 [pii]
AID - 10.1038/nri3401 [doi]
PST - ppublish
SO  - Nat Rev Immunol. 2013 Mar;13(3):176-89. doi: 10.1038/nri3401. Epub 2013 Feb 15.